Andrographolide

Identification

Name
Andrographolide
Accession Number
DB05767
Type
Small Molecule
Groups
Investigational
Description

HMPL-004 is a botanical product extracted from a herb that occurs naturally in China. The herb has an extensive history of use in TCM for the treatment of upper respiratory tract infections and other inflammatory and infectious diseases.

Structure
Thumb
Synonyms
Not Available
External IDs
HMPL-004
Categories
UNII
410105JHGR
CAS number
Not Available
Weight
Average: 350.455
Monoisotopic: 350.209324066
Chemical Formula
C20H30O5
InChI Key
BOJKULTULYSRAS-OTESTREVSA-N
InChI
InChI=1S/C20H30O5/c1-12-4-7-16-19(2,9-8-17(23)20(16,3)11-21)14(12)6-5-13-15(22)10-25-18(13)24/h5,14-17,21-23H,1,4,6-11H2,2-3H3/b13-5+/t14-,15-,16+,17-,19+,20+/m1/s1
IUPAC Name
(3E,4S)-3-{2-[(1R,4aS,5R,6R,8aS)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-decahydronaphthalen-1-yl]ethylidene}-4-hydroxyoxolan-2-one
SMILES
[H]\C(C[C@]1([H])C(=C)CC[C@]2([H])[C@](C)(CO)[C@]([H])(O)CC[C@@]12C)=C1/C(=O)OC[C@@]1([H])O

Pharmacology

Indication

Investigated for use/treatment in ulcerative colitis.

Pharmacodynamics
Not Available
Mechanism of action

HMPL-004 acts on multiple cellular targets in the inflammatory signal transduction pathways resulting in suppressed inflammation cytokine expression including TNF-α, IL-1β and IL-6. HMPL-004 was demonstrated to inhibit TNF-α and IL-1β production in cell-based assays. HMPL-004 is also able to inhibit NF-kB activation. NF-kB is a family of transcriptional factors that regulate a wide spectrum of genes critically involved in host defence and inflammation. The mechanism of action of HMPL-004 was further supported in laboratory IBD animal models. Treatment of IBD rats with HMPL-004 caused a significant drop in plasma cytokine concentrations, including TNF-α and IL-1β.

TargetActionsOrganism
UTumor necrosis factorNot AvailableHuman
UInterleukin-1 betaNot AvailableHuman
UInterleukin-6Not AvailableHuman
UNuclear factor NF-kappa-B p100 subunitNot AvailableHuman
UNuclear factor NF-kappa-B p105 subunitNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when Andrographolide is combined with (4R)-limonene.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Andrographolide is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Andrographolide is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Andrographolide is combined with 5-androstenedione.Experimental, Illicit
AbciximabAndrographolide may increase the anticoagulant activities of Abciximab.Approved
AcebutololAndrographolide may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Andrographolide is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Andrographolide is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolAndrographolide may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Andrographolide is combined with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Andrographolide.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Andrographolide is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Andrographolide is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Andrographolide is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Andrographolide is combined with Alendronic acid.Approved
AliskirenAndrographolide may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Andrographolide is combined with Alminoprofen.Experimental
AloxiprinThe risk or severity of adverse effects can be increased when Andrographolide is combined with Aloxiprin.Experimental
AlprenololAndrographolide may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Andrographolide.Approved, Investigational
AlteplaseAndrographolide may increase the anticoagulant activities of Alteplase.Approved
AmcinonideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Amcinonide.Approved
AmilorideAndrographolide may decrease the antihypertensive activities of Amiloride.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Andrographolide is combined with Aminosalicylic Acid.Approved
AnagrelideAndrographolide may increase the anticoagulant activities of Anagrelide.Approved
AncrodAndrographolide may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Andrographolide is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Andrographolide is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Andrographolide is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Andrographolide is combined with Anisodamine.Investigational
AnistreplaseAndrographolide may increase the anticoagulant activities of Anistreplase.Approved
AntipyrineThe risk or severity of adverse effects can be increased when Andrographolide is combined with Antipyrine.Approved, Investigational
Antithrombin III humanAndrographolide may increase the anticoagulant activities of Antithrombin III human.Approved
AntrafenineThe risk or severity of adverse effects can be increased when Andrographolide is combined with Antrafenine.Approved
ApixabanThe risk or severity of adverse effects can be increased when Andrographolide is combined with Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Andrographolide is combined with Apocynin.Investigational
ApramycinAndrographolide may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Andrographolide.Approved, Investigational
ArbekacinAndrographolide may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinAndrographolide may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanAndrographolide may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololAndrographolide may decrease the antihypertensive activities of Arotinolol.Investigational
AsenapineAndrographolide may decrease the antihypertensive activities of Asenapine.Approved
AstaxanthinAndrographolide may increase the anticoagulant activities of Astaxanthin.Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Andrographolide is combined with Atamestane.Investigational
AtenololAndrographolide may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Andrographolide is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Andrographolide.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Andrographolide is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Andrographolide.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Andrographolide.Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Balsalazide.Approved, Investigational
BatroxobinAndrographolide may increase the anticoagulant activities of Batroxobin.Experimental
BecaplerminAndrographolide may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BefunololAndrographolide may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinAndrographolide may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BemiparinAndrographolide may increase the anticoagulant activities of Bemiparin.Approved, Investigational
BenazeprilThe risk or severity of adverse effects can be increased when Andrographolide is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Andrographolide is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Andrographolide.Approved
BenorilateThe risk or severity of adverse effects can be increased when Andrographolide is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Andrographolide.Withdrawn
BenzthiazideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Andrographolide.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Andrographolide is combined with Benzydamine.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Andrographolide.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Andrographolide is combined with Betamethasone.Approved, Vet Approved
BetaxololAndrographolide may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Andrographolide.Approved, Investigational
BevantololAndrographolide may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Andrographolide is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Andrographolide.Approved, Investigational
BisoprololAndrographolide may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinAndrographolide may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololAndrographolide may decrease the antihypertensive activities of Bopindolol.Approved
BrinaseAndrographolide may increase the anticoagulant activities of Brinase.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Andrographolide is combined with Bromfenac.Approved
BucillamineThe risk or severity of adverse effects can be increased when Andrographolide is combined with Bucillamine.Investigational
BucindololAndrographolide may decrease the antihypertensive activities of Bucindolol.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Andrographolide is combined with Bufexamac.Approved, Experimental
BuflomedilAndrographolide may increase the antiplatelet activities of Buflomedil.Experimental
BufuralolAndrographolide may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Andrographolide is combined with Bumadizone.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Andrographolide.Approved
BupranololAndrographolide may decrease the antihypertensive activities of Bupranolol.Approved
ButylphthalideAndrographolide may increase the antiplatelet activities of Butylphthalide.Investigational
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Andrographolide.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Andrographolide.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Andrographolide is combined with Candoxatril.Experimental
CangrelorAndrographolide may increase the anticoagulant activities of Cangrelor.Approved
CaplacizumabAndrographolide may increase the anticoagulant activities of Caplacizumab.Investigational
CapsaicinThe risk or severity of adverse effects can be increased when Andrographolide is combined with Capsaicin.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Andrographolide is combined with Captopril.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Andrographolide is combined with Carbaspirin calcium.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Andrographolide.Approved
CarprofenThe risk or severity of adverse effects can be increased when Andrographolide is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololAndrographolide may decrease the antihypertensive activities of Carteolol.Approved
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Andrographolide.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Andrographolide is combined with Celecoxib.Approved, Investigational
CeliprololAndrographolide may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinAndrographolide may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Andrographolide.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Andrographolide.Approved, Vet Approved
ChlorphenesinThe risk or severity of adverse effects can be increased when Andrographolide is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Andrographolide.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Andrographolide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Andrographolide is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Andrographolide is combined with Cilazapril.Approved
CilostazolAndrographolide may increase the anticoagulant activities of Cilostazol.Approved, Investigational
CimicoxibThe risk or severity of adverse effects can be increased when Andrographolide is combined with Cimicoxib.Investigational
CinoxacinAndrographolide may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CisplatinThe risk or severity of adverse effects can be increased when Andrographolide is combined with Cisplatin.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Andrographolide is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Andrographolide is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Andrographolide is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Andrographolide is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Andrographolide is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Andrographolide is combined with Clonixin.Approved
ClopidogrelAndrographolide may increase the anticoagulant activities of Clopidogrel.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Andrographolide.Vet Approved
CloranololAndrographolide may decrease the antihypertensive activities of Cloranolol.Experimental
CloricromenAndrographolide may increase the anticoagulant activities of Cloricromen.Experimental
ClorindioneAndrographolide may increase the anticoagulant activities of Clorindione.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of Andrographolide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Andrographolide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Collagenase clostridium histolyticumThe risk or severity of adverse effects can be increased when Andrographolide is combined with Collagenase clostridium histolyticum.Approved, Investigational
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Andrographolide is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Andrographolide is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Andrographolide is combined with Cortisone acetate.Approved, Investigational
CurcuminThe risk or severity of adverse effects can be increased when Andrographolide is combined with Curcumin.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Andrographolide.Experimental
Dabigatran etexilateAndrographolide may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinAndrographolide may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidAndrographolide may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanAndrographolide may increase the anticoagulant activities of Darexaban.Investigational
DasatinibDasatinib may increase the anticoagulant activities of Andrographolide.Approved, Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Andrographolide is combined with Deferasirox.Approved, Investigational
DefibrotideAndrographolide may increase the anticoagulant activities of Defibrotide.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Andrographolide is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Andrographolide is combined with Delapril.Investigational
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Andrographolide is combined with Deoxycholic Acid.Approved
DersalazineThe risk or severity of adverse effects can be increased when Andrographolide is combined with Dersalazine.Investigational
DesipramineAndrographolide may decrease the antihypertensive activities of Desipramine.Approved, Investigational
DesirudinAndrographolide may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Andrographolide is combined with Desmopressin.Approved
DesmoteplaseAndrographolide may increase the anticoagulant activities of Desmoteplase.Investigational
DesonideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Andrographolide is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Andrographolide is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Andrographolide is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DesvenlafaxineDesvenlafaxine may increase the antiplatelet activities of Andrographolide.Approved, Investigational
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Andrographolide is combined with Dexamethasone isonicotinate.Vet Approved
DexibuprofenThe risk or severity of adverse effects can be increased when Andrographolide is combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Andrographolide.Approved, Investigational
DextranAndrographolide may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DibekacinAndrographolide may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when Andrographolide is combined with Dibotermin alfa.Approved, Investigational
DicoumarolAndrographolide may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Andrographolide is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Andrographolide is combined with Diflunisal.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Andrographolide is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Andrographolide is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Andrographolide.Approved
DihydrostreptomycinAndrographolide may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Andrographolide.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Andrographolide.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Andrographolide.Approved
DiphenadioneAndrographolide may increase the anticoagulant activities of Diphenadione.Experimental
DipyridamoleAndrographolide may increase the anticoagulant activities of Dipyridamole.Approved
DitazoleAndrographolide may increase the anticoagulant activities of Ditazole.Approved, Withdrawn
DrospirenoneAndrographolide may increase the hyperkalemic activities of Drospirenone.Approved
Drotrecogin alfaAndrographolide may increase the anticoagulant activities of Drotrecogin alfa.Approved, Investigational, Withdrawn
DroxicamThe risk or severity of adverse effects can be increased when Andrographolide is combined with Droxicam.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Andrographolide is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Andrographolide is combined with E-6201.Investigational
Edetic AcidAndrographolide may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanAndrographolide may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Andrographolide is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Andrographolide is combined with Enalaprilat.Approved
EnoxacinAndrographolide may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinAndrographolide may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Andrographolide.Experimental
EpanololAndrographolide may decrease the antihypertensive activities of Epanolol.Experimental
EpinastineEpinastine may increase the antiplatelet activities of Andrographolide.Approved, Investigational
EpirizoleThe risk or severity of adverse effects can be increased when Andrographolide is combined with Epirizole.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Andrographolide.Experimental
EplerenoneAndrographolide may decrease the antihypertensive activities of Eplerenone.Approved
EplivanserinAndrographolide may increase the anticoagulant activities of Eplivanserin.Investigational
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Andrographolide.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Andrographolide.Approved
EptifibatideAndrographolide may increase the anticoagulant activities of Eptifibatide.Approved, Investigational
EquileninThe risk or severity of adverse effects can be increased when Andrographolide is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Andrographolide is combined with Equilin.Approved
EsatenololAndrographolide may decrease the antihypertensive activities of Esatenolol.Experimental
EsmololAndrographolide may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Andrographolide is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Andrographolide is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Andrographolide.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Andrographolide is combined with Etanercept.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Ethenzamide.Experimental
Ethyl biscoumacetateAndrographolide may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Andrographolide is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Andrographolide is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Andrographolide is combined with Etofenamate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Andrographolide is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Andrographolide is combined with Evening primrose oil.Investigational, Nutraceutical
ExisulindThe risk or severity of adverse effects can be increased when Andrographolide is combined with Exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Andrographolide is combined with Felbinac.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Andrographolide is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Andrographolide is combined with Fenoprofen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Andrographolide.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Andrographolide is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Andrographolide is combined with Feprazone.Experimental
Ferulic acidAndrographolide may increase the anticoagulant activities of Ferulic acid.Experimental
FibrinolysinAndrographolide may increase the anticoagulant activities of Fibrinolysin.Investigational
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Andrographolide.Approved, Investigational
FleroxacinAndrographolide may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Andrographolide.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Andrographolide is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Andrographolide is combined with Fludrocortisone.Approved, Investigational
FluindioneAndrographolide may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineAndrographolide may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Andrographolide is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Andrographolide is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Andrographolide is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Andrographolide is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Andrographolide is combined with Fluorometholone.Approved, Investigational
FluoxetineFluoxetine may increase the antiplatelet activities of Andrographolide.Approved, Vet Approved
FluprednideneThe risk or severity of adverse effects can be increased when Andrographolide is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Andrographolide is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Andrographolide.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Andrographolide is combined with Flurbiprofen.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Andrographolide is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Andrographolide is combined with Fluticasone furoate.Approved
FluvoxamineFluvoxamine may increase the antiplatelet activities of Andrographolide.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Andrographolide.Approved, Nutraceutical, Vet Approved
FondaparinuxAndrographolide may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Andrographolide.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Andrographolide is combined with Formestane.Approved, Investigational, Withdrawn
FramycetinAndrographolide may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
GabexateAndrographolide may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinAndrographolide may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinAndrographolide may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Andrographolide.Approved, Withdrawn
GemifloxacinAndrographolide may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinAndrographolide may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinAndrographolide may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AAndrographolide may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GinsengThe risk or severity of adverse effects can be increased when Andrographolide is combined with Ginseng.Approved, Investigational, Nutraceutical
GlucosamineGlucosamine may increase the antiplatelet activities of Andrographolide.Approved, Investigational
GrepafloxacinAndrographolide may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Andrographolide is combined with Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Andrographolide is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Andrographolide is combined with HE3286.Investigational
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Andrographolide is combined with Hemoglobin crosfumaril.Experimental
HeparinAndrographolide may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Andrographolide is combined with Higenamine.Investigational
HydralazineAndrographolide may decrease the antihypertensive activities of Hydralazine.Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Andrographolide.Approved, Investigational
HydroxytyrosolAndrographolide may increase the antiplatelet activities of Hydroxytyrosol.Investigational
Hygromycin BAndrographolide may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Andrographolide is combined with Ibritumomab tiuxetan.Approved, Investigational
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Andrographolide.Approved
IbudilastIbudilast may increase the antiplatelet activities of Andrographolide.Approved, Investigational
IbuproxamThe risk or severity of adverse effects can be increased when Andrographolide is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Andrographolide is combined with Icatibant.Approved, Investigational
IcosapentThe risk or severity of adverse effects can be increased when Andrographolide is combined with Icosapent.Approved, Nutraceutical
Icosapent ethylAndrographolide may increase the antiplatelet activities of Icosapent ethyl.Approved, Investigational, Nutraceutical
IdraparinuxAndrographolide may increase the anticoagulant activities of Idraparinux.Investigational
IfenprodilAndrographolide may increase the antiplatelet activities of Ifenprodil.Approved, Investigational, Withdrawn
IfetrobanAndrographolide may increase the antiplatelet activities of Ifetroban.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Andrographolide.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Andrographolide is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Andrographolide is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Andrographolide.Approved
IndenololAndrographolide may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenAndrographolide may increase the anticoagulant activities of Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Andrographolide is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Andrographolide is combined with Indoprofen.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Andrographolide.Approved, Investigational
IsepamicinAndrographolide may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Andrographolide is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Andrographolide is combined with Istaroxime.Investigational
KanamycinAndrographolide may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Andrographolide is combined with Kebuzone.Experimental
KetanserinAndrographolide may increase the antiplatelet activities of Ketanserin.Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Andrographolide is combined with Ketoprofen.Approved, Vet Approved
LandiololAndrographolide may decrease the antihypertensive activities of Landiolol.Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Andrographolide.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Andrographolide.Approved, Investigational
LepirudinAndrographolide may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanAndrographolide may increase the anticoagulant activities of Letaxaban.Investigational
LevobetaxololAndrographolide may decrease the antihypertensive activities of Levobetaxolol.Approved, Investigational
LevobunololAndrographolide may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinAndrographolide may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostLimaprost may increase the antiplatelet activities of Andrographolide.Approved, Investigational
LinsidomineAndrographolide may increase the antiplatelet activities of Linsidomine.Experimental
LisinoprilThe risk or severity of adverse effects can be increased when Andrographolide is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Andrographolide is combined with Lisofylline.Investigational
Lithium cationThe serum concentration of Lithium can be increased when it is combined with Andrographolide.Experimental
LomefloxacinAndrographolide may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Andrographolide is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Andrographolide is combined with Lornoxicam.Approved, Investigational
LoteprednolThe risk or severity of adverse effects can be increased when Andrographolide is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Andrographolide is combined with Loxoprofen.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Andrographolide.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Andrographolide is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Andrographolide.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Andrographolide is combined with Magnesium salicylate.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Andrographolide.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Andrographolide is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Andrographolide is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Andrographolide is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Andrographolide is combined with Mefenamic acid.Approved
MelagatranAndrographolide may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Andrographolide is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Andrographolide is combined with Meloxicam.Approved, Vet Approved
MepindololAndrographolide may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Andrographolide is combined with Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Andrographolide.Approved, Investigational, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Andrographolide.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Andrographolide.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Andrographolide is combined with Methyl salicylate.Approved, Vet Approved
MetipranololAndrographolide may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Andrographolide.Approved
MicronomicinAndrographolide may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Andrographolide.Approved, Experimental
MilrinoneMilrinone may increase the antiplatelet activities of Andrographolide.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Andrographolide.Approved
MizoribineThe risk or severity of adverse effects can be increased when Andrographolide is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Andrographolide is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Andrographolide is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Andrographolide is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Andrographolide.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Andrographolide.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Andrographolide.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Andrographolide is combined with Nabumetone.Approved
NadololAndrographolide may decrease the antihypertensive activities of Nadolol.Approved
NadroparinAndrographolide may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatAndrographolide may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Andrographolide.Approved
NaftopidilAndrographolide may increase the antiplatelet activities of Naftopidil.Investigational
Nalidixic AcidAndrographolide may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when Andrographolide is combined with NCX 1022.Investigational
NeamineAndrographolide may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololAndrographolide may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NemonoxacinAndrographolide may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NepafenacThe risk or severity of adverse effects can be increased when Andrographolide is combined with Nepafenac.Approved, Investigational
NetilmicinAndrographolide may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Andrographolide is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Andrographolide is combined with Niflumic Acid.Approved
NimesulideNimesulide may increase the antiplatelet activities of Andrographolide.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Andrographolide is combined with Nitroaspirin.Investigational
NorfloxacinAndrographolide may increase the neuroexcitatory activities of Norfloxacin.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Andrographolide is combined with Obinutuzumab.Approved, Investigational
OfloxacinAndrographolide may increase the neuroexcitatory activities of Ofloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Andrographolide is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Andrographolide.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Andrographolide.Approved
OlsalazineAndrographolide may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Andrographolide is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Andrographolide is combined with Omapatrilat.Investigational
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Andrographolide.Approved, Nutraceutical
OrgoteinThe risk or severity of adverse effects can be increased when Andrographolide is combined with Orgotein.Vet Approved
OtamixabanAndrographolide may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Andrographolide is combined with Oxaprozin.Approved
Oxolinic acidAndrographolide may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololAndrographolide may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Andrographolide.Approved, Withdrawn
OzagrelAndrographolide may increase the anticoagulant activities of Ozagrel.Investigational
PalmidrolThe risk or severity of adverse effects can be increased when Andrographolide is combined with Palmidrol.Experimental, Nutraceutical
PamidronateThe risk or severity of adverse effects can be increased when Andrographolide is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Andrographolide is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Andrographolide is combined with Parecoxib.Approved
ParnaparinAndrographolide may increase the anticoagulant activities of Parnaparin.Approved, Investigational
ParoxetineParoxetine may increase the antiplatelet activities of Andrographolide.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Parthenolide.Approved, Investigational
PazufloxacinAndrographolide may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinAndrographolide may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololAndrographolide may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateAndrographolide may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Andrographolide.Approved
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Andrographolide.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Andrographolide is combined with Perindopril.Approved
PhenindioneAndrographolide may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonAndrographolide may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
Phenyl aminosalicylateThe risk or severity of adverse effects can be increased when Andrographolide is combined with Phenyl aminosalicylate.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Andrographolide is combined with Phenylbutazone.Approved, Vet Approved
PicotamideAndrographolide may increase the anticoagulant activities of Picotamide.Experimental
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Andrographolide.Approved, Investigational
PindololAndrographolide may decrease the antihypertensive activities of Pindolol.Approved, Investigational
Pipemidic acidAndrographolide may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Andrographolide.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Andrographolide.Approved, Investigational
Piromidic acidAndrographolide may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Andrographolide is combined with Piroxicam.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Andrographolide is combined with Pirprofen.Experimental
PitolisantThe risk or severity of adverse effects can be increased when Andrographolide is combined with Pitolisant.Approved, Investigational
Platelet Activating FactorAndrographolide may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinAndrographolide may decrease the excretion rate of Plazomicin which could result in a higher serum level.Approved, Investigational
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Andrographolide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Pomalidomide.Approved
Potassium CitrateAndrographolide may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PractololAndrographolide may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Andrographolide.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Andrographolide is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Andrographolide is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Andrographolide is combined with Prasterone sulfate.Investigational
PrasugrelAndrographolide may increase the anticoagulant activities of Prasugrel.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Andrographolide is combined with Prednicarbate.Approved, Investigational
PrednisoneThe risk or severity of adverse effects can be increased when Andrographolide is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Andrographolide is combined with Pregnenolone.Approved, Experimental, Investigational
ProbenecidThe serum concentration of Andrographolide can be increased when it is combined with Probenecid.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Andrographolide is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Andrographolide is combined with Propacetamol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Andrographolide is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Andrographolide is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Andrographolide.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Andrographolide.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Andrographolide.Vet Approved
Protein CAndrographolide may increase the anticoagulant activities of Protein C.Approved
Protein S humanAndrographolide may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeAndrographolide may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinAndrographolide may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Andrographolide.Investigational
PuromycinAndrographolide may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Andrographolide is combined with Quinapril.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Andrographolide.Approved
RamatrobanAndrographolide may increase the antiplatelet activities of Ramatroban.Investigational
RamiprilThe risk or severity of adverse effects can be increased when Andrographolide is combined with Ramipril.Approved
RelcovaptanAndrographolide may increase the antiplatelet activities of Relcovaptan.Investigational
RescinnamineThe risk or severity of adverse effects can be increased when Andrographolide is combined with Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Andrographolide is combined with Resveratrol.Approved, Experimental, Investigational
ReteplaseAndrographolide may increase the anticoagulant activities of Reteplase.Approved, Investigational
ReviparinAndrographolide may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinAndrographolide may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RidogrelRidogrel may increase the antiplatelet activities of Andrographolide.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Andrographolide is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Andrographolide is combined with Risedronate.Approved, Investigational
RivaroxabanAndrographolide may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Andrographolide is combined with Rofecoxib.Approved, Investigational, Withdrawn
RosoxacinAndrographolide may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinAndrographolide may increase the neuroexcitatory activities of Rufloxacin.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Andrographolide.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Andrographolide is combined with Salicylic acid.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Andrographolide is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Andrographolide.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Andrographolide.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Andrographolide.Approved, Investigational
SarpogrelateAndrographolide may increase the anticoagulant activities of Sarpogrelate.Investigational
SaruplaseAndrographolide may increase the anticoagulant activities of Saruplase.Experimental
SelexipagAndrographolide may increase the anticoagulant activities of Selexipag.Approved
SeliciclibThe risk or severity of adverse effects can be increased when Andrographolide is combined with Seliciclib.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Andrographolide is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Andrographolide is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Andrographolide is combined with Serrapeptase.Investigational
SevofluraneSevoflurane may increase the antiplatelet activities of Andrographolide.Approved, Vet Approved
SisomicinAndrographolide may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinAndrographolide may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium CitrateThe risk or severity of bleeding can be increased when Andrographolide is combined with Sodium Citrate.Approved, Investigational
SotalolAndrographolide may decrease the antihypertensive activities of Sotalol.Approved
SparfloxacinAndrographolide may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpiraprilThe risk or severity of adverse effects can be increased when Andrographolide is combined with Spirapril.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Andrographolide.Investigational
StreptokinaseAndrographolide may increase the anticoagulant activities of Streptokinase.Approved, Investigational
StreptomycinAndrographolide may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Andrographolide is combined with Sulfasalazine.Approved
SulodexideAndrographolide may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Andrographolide.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Andrographolide is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Andrographolide is combined with Suxibuzone.Experimental
TacrolimusAndrographolide may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Andrographolide.Approved
TalinololAndrographolide may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Andrographolide.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Andrographolide.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Andrographolide.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Andrographolide is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Andrographolide is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Andrographolide.Approved, Investigational
TemafloxacinAndrographolide may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Andrographolide is combined with Temocapril.Experimental, Investigational
TenecteplaseAndrographolide may increase the anticoagulant activities of Tenecteplase.Approved
TenidapThe risk or severity of adverse effects can be increased when Andrographolide is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Andrographolide is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Andrographolide is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Andrographolide is combined with Tepoxalin.Vet Approved
TerbutalineAndrographolide may decrease the antihypertensive activities of Terbutaline.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Teriflunomide.Approved
TertatololAndrographolide may decrease the antihypertensive activities of Tertatolol.Experimental
TesmilifeneTesmilifene may increase the antiplatelet activities of Andrographolide.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Andrographolide is combined with Tiaprofenic acid.Approved
TicagrelorAndrographolide may increase the anticoagulant activities of Ticagrelor.Approved
TiclopidineAndrographolide may increase the anticoagulant activities of Ticlopidine.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Andrographolide is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololAndrographolide may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Andrographolide is combined with Tinoridine.Investigational
TinzaparinAndrographolide may increase the anticoagulant activities of Tinzaparin.Approved
TioclomarolAndrographolide may increase the anticoagulant activities of Tioclomarol.Experimental
TipranavirTipranavir may increase the antiplatelet activities of Andrographolide.Approved, Investigational
TirofibanAndrographolide may increase the anticoagulant activities of Tirofiban.Approved
TixocortolThe risk or severity of adverse effects can be increased when Andrographolide is combined with Tixocortol.Approved, Withdrawn
TobramycinAndrographolide may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Andrographolide is combined with Tolmetin.Approved
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Andrographolide.Approved
TositumomabThe risk or severity of adverse effects can be increased when Andrographolide is combined with Tositumomab.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Andrographolide is combined with Trandolapril.Approved
TranilastAndrographolide may increase the antiplatelet activities of Tranilast.Approved, Investigational
TrapidilAndrographolide may increase the antiplatelet activities of Trapidil.Approved
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Andrographolide.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Andrographolide.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Andrographolide is combined with Triamcinolone.Approved, Vet Approved
TriamtereneAndrographolide may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Andrographolide.Approved, Vet Approved
TriflusalAndrographolide may increase the anticoagulant activities of Triflusal.Approved, Investigational
TriptolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Triptolide.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Andrographolide is combined with Trolamine salicylate.Approved
TrovafloxacinAndrographolide may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinAndrographolide may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Andrographolide is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Andrographolide.Approved, Investigational
UrokinaseAndrographolide may increase the anticoagulant activities of Urokinase.Approved, Investigational, Withdrawn
ValdecoxibThe risk or severity of adverse effects can be increased when Andrographolide is combined with Valdecoxib.Approved, Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Andrographolide.Approved, Investigational
VenlafaxineVenlafaxine may increase the antiplatelet activities of Andrographolide.Approved
Vitamin EVitamin E may increase the antiplatelet activities of Andrographolide.Approved, Nutraceutical, Vet Approved
VorapaxarAndrographolide may increase the anticoagulant activities of Vorapaxar.Approved
WarfarinAndrographolide may increase the anticoagulant activities of Warfarin.Approved
XimelagatranAndrographolide may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Andrographolide is combined with Zaltoprofen.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Andrographolide.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Andrographolide is combined with Zofenopril.Experimental
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Andrographolide.Withdrawn
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
5318517
PubChem Substance
347827741
ChemSpider
4477067
ChEBI
65408
ChEMBL
CHEMBL186141
Wikipedia
Andrographolide

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1, 2CompletedTreatmentRelapsing Remitting Multiple Sclerosis (RRMS)1
1, 2RecruitingTreatmentMultiple Sclerosis, Primary Progressive / Secondary Progressive Multiple Sclerosis (SPMS)1
2CompletedTreatmentUlcerative Colitis (UC)1
3TerminatedTreatmentUlcerative Colitis (UC)2

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.284 mg/mLALOGPS
logP1.57ALOGPS
logP1.66ChemAxon
logS-3.1ALOGPS
pKa (Strongest Acidic)13.48ChemAxon
pKa (Strongest Basic)-2.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area86.99 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity94.93 m3·mol-1ChemAxon
Polarizability38.65 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as gamma butyrolactones. These are compounds containing a gamma butyrolactone moiety, which consists of an aliphatic five-member ring with four carbon atoms, one oxygen atom, and bears a ketone group on the carbon adjacent to the oxygen atom.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Lactones
Sub Class
Gamma butyrolactones
Direct Parent
Gamma butyrolactones
Alternative Parents
Tetrahydrofurans / Enoate esters / Secondary alcohols / Cyclic alcohols and derivatives / Oxacyclic compounds / Monocarboxylic acids and derivatives / Primary alcohols / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Gamma butyrolactone / Cyclic alcohol / Tetrahydrofuran / Enoate ester / Alpha,beta-unsaturated carboxylic ester / Carboxylic acid ester / Secondary alcohol / Monocarboxylic acid or derivatives / Carboxylic acid derivative / Oxacycle
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
secondary alcohol, primary alcohol, gamma-lactone, carbobicyclic compound, labdane diterpenoid (CHEBI:65408)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Tumor necrosis factor receptor binding
Specific Function
Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct ac...
Gene Name
TNF
Uniprot ID
P01375
Uniprot Name
Tumor necrosis factor
Molecular Weight
25644.15 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Protein domain specific binding
Specific Function
Potent proinflammatory cytokine. Initially discovered as the major endogenous pyrogen, induces prostaglandin synthesis, neutrophil influx and activation, T-cell activation and cytokine production, ...
Gene Name
IL1B
Uniprot ID
P01584
Uniprot Name
Interleukin-1 beta
Molecular Weight
30747.7 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Interleukin-6 receptor binding
Specific Function
Cytokine with a wide variety of biological functions. It is a potent inducer of the acute phase response. Plays an essential role in the final differentiation of B-cells into Ig-secreting cells Inv...
Gene Name
IL6
Uniprot ID
P05231
Uniprot Name
Interleukin-6
Molecular Weight
23717.965 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Transcriptional activator activity, rna polymerase ii core promoter proximal region sequence-specific binding
Specific Function
NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related...
Gene Name
NFKB2
Uniprot ID
Q00653
Uniprot Name
Nuclear factor NF-kappa-B p100 subunit
Molecular Weight
96748.355 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Transcriptional repressor activity, rna polymerase ii transcription regulatory region sequence-specific binding
Specific Function
NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related...
Gene Name
NFKB1
Uniprot ID
P19838
Uniprot Name
Nuclear factor NF-kappa-B p105 subunit
Molecular Weight
105355.175 Da

Drug created on November 18, 2007 11:27 / Updated on August 02, 2018 05:32